Loading...
Found 6 Renal Cell Carcinoma trials
A listing of Renal Cell Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Sort by:
- Sort by
- Last updated
This study investigates a treatment approach for renal cell carcinoma that has spread to other parts of the body. The purpose of this study is to evaluate the effectiveness of a specific therapy called total consolidative metastasis-and-primary directed therapy (MPDT) in patients who have shown stable disease or partial response …
This study investigates the use of investigational medications, specifically pembrolizumab alone or in combination with lenvatinib, for treating high risk renal cell carcinoma. The purpose of this study is to see how these medications affect the immune system's response to the cancer when given before and after surgery to remove …
This study investigates advanced renal cell carcinoma.The study evaluates the safety and tolerability of investigational medications in patients with this condition.Who can participate: Adults aged 18 or older with a confirmed diagnosis of RCC and no prior systemic therapy for RCC may participate. Participants must have adequate organ function and …
This study investigates the effectiveness of two different radiation therapy approaches, fractionated stereotactic radiosurgery (FSRS) and single fraction stereotactic radiosurgery (SRS), in treating patients with cancer that has spread to the brain. SRS involves delivering a single large dose of radiation to the tumor, while FSRS spreads the dose over …
This study investigates the safety and effectiveness of an investigational medication in combination with immuno-oncology agents for individuals with advanced or metastatic solid tumors that cannot be surgically removed. The purpose of this study is to understand how the investigational medication, when used alone or with other treatments like nivolumab, …
The purpose of this study is to investigate the effectiveness of an investigational medication in patients with HER2-positive solid tumors that are locally advanced, unresectable, or metastatic. In this study, HER2-positive is identified as IHC 3+. The study focuses on patients who have previously received systemic treatment for their condition …
Please choose between Voice or SMS based delivery of verification code
or